French pen­ny stock will no longer knock on FDA door for ap­proval in a cer­tain type of blood can­cer

Things are not look­ing up for the French biotech Ery­tech Phar­ma.

The com­pa­ny is knock­ing off its plan to get FDA ap­proval for its drug Gras­pa in hy­per­sen­si­tive acute lym­phoblas­tic leukemia (ALL), fol­low­ing feed­back from the reg­u­la­tors, it said in a press re­lease Wednes­day af­ter­noon. ALL is the com­mon type of child­hood can­cer di­ag­nosed in ap­prox­i­mate­ly 5,000 new cas­es each year in the Unit­ed States.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER